China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
You may also be interested in...
Roche’s Pirfenidone Bet Validates China Venture
China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.
Cenova Touts Experience In Assessing Risk Of China Drug Development With Aslan Financing
Taking on the risk of a biotech investment in China takes experience, according to Shanghai-based Cenova Ventures, as a recent Series B finance round with Aslan Pharmaceuticals shows.
Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.